Dr. Lonial on Novel Mechanisms in Multiple Myeloma

Sagar Lonial, MD
Published: Tuesday, Dec 29, 2015



Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

The monoclonal antibody elotuzumab (Empliciti) works through activation of natural killer cells, Lonial explains. Daratumumab (Darzalex), another monoclonal antibody, induces antibody-dependent cell-mediated cytotoxicity and also works through direct signaling inhibition. Antibodies that are in development include CD138-targeted agents and PD-1/PD-L1 agents.

Next steps with these agents include investigating them in earlier lines of therapy, Lonial adds. Incorporating these antibodies as an upfront treatment approach and in combination with other therapies will likely be part of future treatment paradigms. Secondly, novel ways of administering agents such as panobinostat and filanesib should also be researched, Lonial says.


Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

The monoclonal antibody elotuzumab (Empliciti) works through activation of natural killer cells, Lonial explains. Daratumumab (Darzalex), another monoclonal antibody, induces antibody-dependent cell-mediated cytotoxicity and also works through direct signaling inhibition. Antibodies that are in development include CD138-targeted agents and PD-1/PD-L1 agents.

Next steps with these agents include investigating them in earlier lines of therapy, Lonial adds. Incorporating these antibodies as an upfront treatment approach and in combination with other therapies will likely be part of future treatment paradigms. Secondly, novel ways of administering agents such as panobinostat and filanesib should also be researched, Lonial says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x